Here are the 10-K annual reports from Collegium Pharmaceutical, Inc. (COLL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow COLL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COLL filings page.
Collegium Pharmaceutical files its annual report describing a diversified pain and ADHD portfolio and a heavily regulated operating environment. The company markets Xtampza ER, Belbuca, Symproic, the Nucynta Products, and ADHD drug Jornay PM in the United States.
The September 2024 acquisition of Ironshore added Jornay PM and expanded Collegium into neuropsychiatry. As of June 30, 2025, non-affiliate common stock held an aggregate market value of about $926.4 million, and as of January 31, 2026 there were 31,753,211 common shares outstanding.
The filing highlights extensive opioid and stimulant regulation, REMS obligations, DEA quota controls, and broad healthcare fraud and abuse laws. It also notes patent and exclusivity timelines, looming generic competition for Nucynta, and growing policy pressure on U.S. drug pricing and reimbursement.